SCHEMBL4892925

SCHEMBL4892925

Cc1ccc(CN2C(=O)C(=Cc3ccc(-c4ccc(C(=O)O)cc4)o3)SC2=S)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.75
ENPP2 Q13822 2/20 0.68
MAPT P10636 4/20 0.66
TDP1 Q9NUW8 2/20 0.66
APEX1 P27695 2/20 0.66
KDM4E B2RXH2 1/20 0.66
MEN1 O00255 3/20 0.64
ALDH1A1 P00352 3/20 0.64
KMT2A Q03164 3/20 0.64
MCL1 Q07820 3/20 0.64
POLB P06746 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
RECQL P46063 2/20 0.64
EIF4E P06730 1/20 0.64
EIF4G1 Q04637 1/20 0.64
THRB P10828 1/20 0.64
PKM P14618 1/20 0.63
PTPN7 P35236 1/20 0.63
PTPN12 Q05209 1/20 0.63
PTPN22 Q9Y2R2 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892919 1.00 STAT3 (0.75) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL20339302 0.91 STAT3 (0.74) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL20339299 0.91 STAT3 (0.74) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL23145046 0.91 STAT3 (0.76) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL46211 0.91 STAT3 (0.76) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL18301010 0.91 STAT3 (0.76) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL20339643 0.91 ENPP2 (0.82) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL20339641 0.91 ENPP2 (0.82) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL16687571 0.90 ENPP2 (0.82) STAT3ENPP2MAPTTDP1APEX1
SCHEMBL20339287 0.90 STAT3 (0.72) STAT3ENPP2MAPTTDP1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US claimed
EP-1830848-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS Cell Therapeutics Europe S.R.L. (IT) 2007-09-12 EP claimed
WO-2006066846-A1 USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS CELL THERAPEUTICS EUROPE S.R.L. (IT) 2006-06-29 WO claimed
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents CELL THERAPEUTICS, INC. (US) 2008-10-23 US disclosed
US-20040002526-A1 Phospholipase D inhibitors and uses thereof CELL THERAPEUTICS, INC. 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002526-A1 Phospholipase D inhibitors and uses thereof PLD2, PLD1, PLA2G2D STAT3 1493/4885ENPP2 44/4885MAPT 4292/4885
US-20080261980-A1 Use of Thiazolidinone Derivatives as Antiangiogenic Agents EP300, HIF1A, HIF1AN STAT3 329/4885ENPP2 2878/4885MAPT 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.